1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Supportive care measures: new trials by email Literature Review of Supportive care measures trials Research Report on Supportive care measures
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan - Gastroesophageal Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 473 | 2024-05-03 | 2026-10-22 |
| Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 614 | 2023-12-15 | 2026-11-03 |
Adenocarcinoma Of Esophagus (1) · Carcinoma, Non-Small-Cell Lung (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Brazil (2) · Canada (2) · Chile (2) · China (2) · Colombia (2) · Denmark (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Mexico (2) · Peru (2) · Poland (2) · South Korea (2) · Spain (2)
2023 (2)